MedTrace Logo

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

NCT05637879 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-04-24

No results posted yet for this study

Summary

A double-blind randomized placebo-controlled trial to further investigate glecaprevir/pibrentasvir (GLE/PIB), a direct acting antiviral (DAA) that has been associated with posttraumatic stress disorder (PTSD) symptom improvement when prescribed for the treatment of chronic hepatitis C viral infection (HCV).

Conditions

Interventions

DRUG

Glecaprevir/pibrentasvir

Direct-acting antiviral, Food \& Drug Administration (FDA) approved for the treatment of hepatitis C viral infection

OTHER

Placebo

Compounded, inactive pill equal in appearance to active study drug

Sponsors & Collaborators

  • White River Junction Veterans Affairs Medical Center

    lead FED

Principal Investigators

  • Bradley V Watts, MD, MPH · US Department of Veterans Affairs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2025-12-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05637879 on ClinicalTrials.gov